Evaluation of Hepatic Impairment Dosing Recommendations in FDA-Approved Product Labels-Reference-Cited by-同舟云学术

Evaluation of Hepatic Impairment Dosing Recommendations in FDA-Approved Product Labels

Published:2013-07-07 Issue:9 Volume:53 Page:962-966
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Chang Yang¹,Burckart Gilbert J.²,Lesko Lawrence J.³,Dowling Thomas C.¹

Affiliation:

1. School of Pharmacy; University of Maryland; Baltimore MD USA

2. Office of Clinical Pharmacology, Office of Translational Sciences; Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Silver Spring MD USA

3. Center for Pharmacometrics and Systems Pharmacology; University of Florida College of Pharmacy; Orlando FL USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.128/fullpdf

Reference24 articles.

1. Deaths: final data for 2007;Xu;Natl Vital Stat Rep.,2010

2. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008;Younossi;Clin Gastroenterol Hepatol.,2011

3. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction;Verbeeck;Eur J Clin Pharmacol.,2008

4. Dose adjustment in patients with liver disease;Delcò;Drug Saf.,2005

5. U.S. Food and Drug Administration http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf 2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug transporters in drug disposition – the year 2022 in review;Drug Metabolism Reviews;2023-09-06

2. Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs;Clinical Pharmacology & Therapeutics;2023-01-15

3. Expert Consensus on Diagnosis and Treatment of End-Stage Liver Disease Complicated with Infections;Infectious Diseases & Immunity;2022-06-28

4. Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications—A Systematic Analysis of SmPCs/PI of Major Drug Markets;Journal of Clinical Medicine;2022-03-30

5. Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial;Clinical Pharmacology in Drug Development;2022-02-16